Professor Ludwig Kappos University Hospital Petersgraben, Basle, Switzerland, and colleagues, as part of the BENEFIT study, did a study of 468 patients who had shown early symptoms of MS. Of these, 292 were randomised to receive 250µg interferon beta-1b and 176 to receive placebo, subcutaneously every other day for two years, or until they were diagnosed with clinically definite multiple sclerosis (CDMS). After diagnosis of CDMS or completion of two-years of treatment, the patients were then eligible to enter a follow-up phase to receive interferon beta-1b treatment.
Of the patients originally enrolled, 89% entered the follow-up phase, while 84% completed the three-years post-randomisation follow up (2 years in initial phase, one year follow up phase). The study measured patients’ disability status using the expanded disability status scale (EDSS) and found that early treatment with interferon beta-1b reduced the risk for progression of disability by 40% compared with delayed treatment. And whilst 51% of patients in the delayed-treatment group developed CDMS, only 37% of the patients who received early treatment with interferon beta-1b developed CDMS. Thus early treatment reduced the risk of developing CDMS by 41%.
The authors conclude: “Our data suggest that early initiation of treatment with interferon-1b prevents the development of confirmed disability, supporting its use after the first manifestation of relapsing-remitting MS.”
In an accompanying Comment, Dr Sean Pittock, Mayo Clinic of Medicine, Rochester, Minnesota, USA, says: “Kappos and colleagues have set a new standard against which future extension trials will be compared.”
He concludes: “The results should, however, be interpreted with care because the magnitude of benefit, although significant, is clinically small. This follow-up should not be misconstrued as evidence for a treat all approach.”
Tony Kirby | alfa
23.03.2017 | Technische Universität München
How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
23.03.2017 | Life Sciences
23.03.2017 | Power and Electrical Engineering
23.03.2017 | Earth Sciences